ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field

ConclusionMost ypT0N + lymph nodes are located within the neoadjuvant radiation field. Although a small heterogeneous population was included, this might be due to an inadequate response to neoadjuvant chemoradiotherapy leading to a trend towards worse PFS and OS in ypT0N + patients. Larger studies need to validate our findings.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

Condition:   Esophageal Squamous Cell Carcinoma Interventions:   Drug: Paclitaxel, Cisplatin;   Radiation: neoadjuvant chemoradiation therapy Sponsor:   Henan Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Radiation therapy for nCRT could downstage clinically suspected nodal metastasis. However, such therapy was ineffective when used to treat nodes that were not suspicious for metastasis. Because significant numbers of residual metastases were identified irrespective of coverage by the radiation field, lymphadenectomy should be performed to ensure complete removal of residual nodal metastases after nCRT. PMID: 31624713 [PubMed]
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
To assess the comparative efficacy and safety of elective nodal irradiation (ENI) and involved-field irradiation (IFI) in patients with esophageal cancer (EC) receiving neoadjuvant chemoradiotherapy plus surge...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Conclusions: Neoadjuvant radiation dose impacts pathological response in terms of pMR in oesophageal cancer patients. No radiation dose-response effect was observed for pCR. Further prospective trials are needed to investigate the dose-response relation in terms of pCR. PMID: 31432736 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Esophageal cancer incidence in the Western world has risen over the past decades, with adenocarcinomas now being more prevalent than squamous cell carcinomas [1]. Alcohol intake, tobacco smoking and overweight are key risk factors, especially for adenocarcinomas. The disease is rarely curable with a 5-year overall survival of approximately 20% [2,3]. Standard treatment consists of neoadjuvant chemoradiotherapy followed by surgery [4].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Purpose: The purpose of this study was to evaluate predictors of cardiac events in esophageal cancer patients treated with neoadjuvant chemoradiotherapy (NA CRT) followed by surgery compared with surgery alone. Materials and Methods: We retrospectively identified patients treated for esophageal cancer between 2006 and 2016. A total of 123 patients were identified; 70 were treated with surgery alone, and 53 were treated with NA CRT. Cardiac events were scored based on Common Terminology Criteria for Adverse Events (version 4.03), and dosimetric data was compiled for all patients who received radiation. Univariate analy...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
This study combined clinical outcome data with systematic evaluation of pulmonary physiology to determine the impact of nCRT on pulmonary physiology and clinical outcomes in locally advanced oesophageal cancer. METHODS: Consecutive patients treated between 2010 and 2016 were included. Three-dimensional conformal radiation was standard, with a lung dose-volume histogram of V20 less than 25 per cent, and total radiation between 40 and 41·4 Gy. Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) were assessed at baseline ...
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
Conditions:   Esophageal Squamous Cell Carcinoma by AJCC V8 Stage;   Resectable Esophageal Cancer Interventions:   Drug: Toripalimab;   Drug: Paclitaxel/cisplatin;   Radiation: Intensity-modulated radiotherapy;   Procedure: Esophagectomy Sponsor:   Jianhua Fu Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Databases & Libraries | Esophagus Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Statistics | Study | Surgery